RG
ATRA icon

Redmile Group’s Atara Biotherapeutics ATRA Stock Holding History

Redmile Group’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.09M Hold
441,701
– – 0.14% 33
2025
Q4 		$7.99M Hold
441,701
– – 0.59% 25
2025
Q3 		$6.33M Hold
441,701
– – 0.62% 26
2025
Q2 		$3.41M Hold
441,701
– – 0.36% 37
2025
Q1 		$2.62M Hold
441,701
– – 0.25% 47
2024
Q4 		$5.88M Sell
441,701
-10,569
-2% -$111K 0.41% 45
2024
Q3 		$3.68M Hold
452,270
– – 0.22% 49
2024
Q2 		$3.84M Buy
452,270
+81,738
+22% +$1.23M 0.23% 49
2024
Q1 		$6.43M Buy
370,532
+6,274
+2% +$111K 0.24% 65
2023
Q4 		$4.67M Buy
364,258
+113,025
+45% +$2.64M 0.17% 57
2023
Q3 		$9.3M Buy
251,233
+9,308
+4% +$414K 0.44% 45
2023
Q2 		$9.74M Buy
241,925
+17,443
+8% +$986K 0.37% 49
2023
Q1 		$16.3M Sell
224,482
-25,228
-10% -$2.45M 0.71% 45
2022
Q4 		$20.5M Hold
249,710
– – 0.84% 35
2022
Q3 		$23.6M Hold
249,710
– – 0.92% 35
2022
Q2 		$48.6M Sell
249,710
-126
-0.1% -$20.6K 1.86% 18
2022
Q1 		$58M Sell
249,836
-7,675
-3% -$2.44M 1.81% 17
2021
Q4 		$101M Sell
257,511
-1,140
-0.4% -$480K 2.31% 12
2021
Q3 		$116M Buy
258,651
+668
+0.3% +$239K 2.02% 16
2021
Q2 		$100M Sell
257,983
-17,426
-6% -$6.22M 1.48% 21
2021
Q1 		$98.9M Buy
275,409
+886
+0.3% +$392K 1.39% 22
2020
Q4 		$135M Sell
274,523
-3,032
-1% -$1.4M 1.63% 19
2020
Q3 		$89.9M Buy
277,555
+3,820
+1% +$1.3M 1.65% 16
2020
Q2 		$99.7M Buy
273,735
+62,000
+29% +$15.7M 1.84% 15
2020
Q1 		$45M Buy
211,735
+25,792
+14% +$8.19M 1.26% 29
2019
Q4 		$76.6M Buy
185,943
+5,154
+3% +$1.78M 1.83% 18
2019
Q3 		$63.8M Sell
180,789
-3,248
-2% -$1.21M 2.14% 16
2019
Q2 		$92.5M Buy
184,037
+4,620
+3% +$3.26M 2.62% 10
2019
Q1 		$178M Buy
179,417
+2,832
+2% +$2.63M 5.22% 4
2018
Q4 		$153M Buy
176,585
+7,836
+5% +$7.28M 6.17% 2
2018
Q3 		$174M Buy
168,749
+3,684
+2% +$3.6M 5.37% 2
2018
Q2 		$152M Sell
165,065
-4,376
-3% -$4.7M 5.15% 3
2018
Q1 		$165M Buy
169,441
+56,801
+50% +$51.8M 6.38% 2
2017
Q4 		$51M Sell
112,640
-2,948
-3% -$1.09M 2.22% 15
2017
Q3 		$47.8M Buy
115,588
+6,226
+6% +$2.35M 2.36% 13
2017
Q2 		$38.3M Sell
109,362
-3
-0% -$1.16K 2.33% 12
2017
Q1 		$56.2M Buy
109,365
+2,527
+2% +$1.05M 3.65% 6
2016
Q4 		$37.9M Buy
106,838
+25,973
+32% +$11M 3.27% 11
2016
Q3 		$43.2M Sell
80,865
-15,494
-16% -$8.41M 3.44% 11
2016
Q2 		$54.2M Buy
96,359
+5,328
+6% +$2.56M 5.18% 5
2016
Q1 		$43.3M Buy
91,031
+29,633
+48% +$13.3M 4.43% 7
2015
Q4 		$40.5M Buy
61,398
+19,407
+46% +$14.7M 3.03% 15
2015
Q3 		$33M Buy
41,991
+27,085
+182% +$33M 2.5% 17
2015
Q2 		$19.7M Buy
14,906
+4,298
+41% +$4.93M 1.61% 24
2015
Q1 		$11M Buy
10,608
+37
+0.4% +$24.5K 0.99% 36
2014
Q4 		$7.07M Buy
+10,571
New +$6.46M 0.77% 38

Other funds holding ATRA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Redmile Group's ATRA Position: Q1 2026 in Review

Redmile Group held its Atara Biotherapeutics (ATRA) position steady in Q1 2026 at 441,701 shares worth $2.09M. The position accounts for 0.14% of the portfolio, ranked #33.

Redmile Group first reported a position in ATRA in Q4 2014 and has held it in 46 quarters since. The position peaked at $178M in Q1 2019. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.

  • Redmile Group held 441,701 shares of Atara Biotherapeutics worth $2.09M as of Q1 2026.
  • Redmile Group left its Atara Biotherapeutics share count unchanged in Q1 2026.
  • Atara Biotherapeutics made up 0.14% of Redmile Group's portfolio in Q1 2026, its #33 holding.
  • Redmile Group first reported a position in Atara Biotherapeutics in Q4 2014 and has held it in 46 quarters since.
  • Redmile Group's Atara Biotherapeutics position peaked at $178M in Q1 2019.
  • 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.

Based on Redmile Group's 13F filing for Q1 2026, filed 15 May 2026.